Zhangjiajie

Researchers are evaluating the safety and effectiveness of 9MW1911 in people with Chronic Obstructive Pulmonary Disease (COPD) through a Phase II, multicenter, double-blind, randomized, placebo-controlled clinical trial. The study focuses on patients aged 40 to 75 years who have a history of moderate to severe COPD exacerbations and moderate-to-severe COPD lung function impairment. This trial aims to compare 9MW1911 to a placebo to better understand its impact on COPD symptoms and exacerbations. Participants will be assigned to receive either intravenous 9MW1911 or a placebo every 28 days. The treatment period lasts 52 weeks, during which the study drug is administered monthly. The trial includes careful monitoring and evaluation of the participants' lung function and health status throughout this time to assess the effects of the treatment. During the study, participants will undergo various assessments including lung function tests and monitoring for COPD flare-ups or exacerbations. The primary outcome measured is the annual rate of moderate to severe acute COPD exacerbations over 52 weeks. Safety evaluations and regular health checks will also be conducted to ensure participant well-being. The total duration of participation in the trial is one year, providing comprehensive data on treatment effects and safety.

Researchers are evaluating the safety and effectiveness of PM8002 combined with Nab-Paclitaxel compared to a placebo combined with Nab-Paclitaxel as the first treatment for women with inoperable locally advanced or metastatic triple-negative breast cancer (TNBC). This is a multicenter, randomized, double-blind Phase III study focusing on this aggressive breast cancer type which lacks three common receptors and has limited treatment options. Participants will receive either PM8002 at 20 mg/kg or a matching placebo, both given through intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. All participants will also receive Nab-Paclitaxel at 100 mg/m2 via IV infusion on Days 1, 8, and 15 of the same 28-day cycle. Treatments will continue according to the study protocol as first-line therapy for their cancer. During the study, researchers will monitor participants for progression-free survival and overall survival, with assessments conducted up to approximately 37 months from the first patient enrolled. Participants will undergo regular evaluations including physical exams, laboratory tests, and imaging scans to measure tumor response and safety. The study includes monitoring for adverse effects and adherence to treatment schedules to ensure participant safety and collect comprehensive data on treatment outcomes.